Compile Data Set for Download or QSAR
maximum 50k data
Found 22 Enz. Inhib. hit(s) with all data for entry = 189
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205085(US9556145, example 5 | methyl 3-chloro-2-(((3R,6R)...)
Affinity DataIC50:  11nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 10 | US9556145, example 11)
Affinity DataIC50:  11nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205088(US9556145, example 8 | methyl 3-fluoro-2-{[(3r,6r)...)
Affinity DataIC50:  24.9nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50084382(CHEMBL3426138 | US9556145, example 1)
Affinity DataIC50:  26nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205083(US9556145, example 3 | methyl 2-{[(3r,6r)-6- methy...)
Affinity DataIC50:  28nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205084(US9556145, example 4 | methyl 5-bromo-2- {[(3r,6r)...)
Affinity DataIC50:  28.9nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205086(US9556145, example 6 | dimethyl 2-{[(3r,6r)-6-meth...)
Affinity DataIC50:  30.8nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 10 | US9556145, example 11)
Affinity DataIC50:  31nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205083(US9556145, example 3 | methyl 2-{[(3r,6r)-6- methy...)
Affinity DataIC50:  57nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205084(US9556145, example 4 | methyl 5-bromo-2- {[(3r,6r)...)
Affinity DataIC50:  60nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205087(US9556145, example 7 | methyl 2-methyl-6-{[(3r,6r)...)
Affinity DataIC50:  82.6nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 10 | US9556145, example 11)
Affinity DataIC50:  96nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205089(US9556145, example 9 | methyl 2-{[(3r,6r)-1-{[6- m...)
Affinity DataIC50:  406nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205086(US9556145, example 6 | dimethyl 2-{[(3r,6r)-6-meth...)
Affinity DataIC50:  526nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205090(US9556145, example 10 | US9556145, example 11)
Affinity DataIC50:  597nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205085(US9556145, example 5 | methyl 3-chloro-2-(((3R,6R)...)
Affinity DataIC50:  953nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50084382(CHEMBL3426138 | US9556145, example 1)
Affinity DataIC50:  1.40E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205087(US9556145, example 7 | methyl 2-methyl-6-{[(3r,6r)...)
Affinity DataIC50:  1.47E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205088(US9556145, example 8 | methyl 3-fluoro-2-{[(3r,6r)...)
Affinity DataIC50:  1.69E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205092(US9556145, example 12)
Affinity DataIC50:  2.11E+3nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205092(US9556145, example 12)
Affinity DataIC50:  1.00E+4nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM205089(US9556145, example 9 | methyl 2-{[(3r,6r)-1-{[6- m...)
Affinity DataIC50:  1.00E+4nMAssay Description:TBDIn a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent